^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GTA102

i
Other names: GTA102
Associations
Trials
Company:
Glycostem
Drug class:
NK cell stimulant
Related drugs:
Associations
Trials
over3years
[VIRTUAL] Enhancing functionality of NK cells towards colorectal cancer cell lines (CIMT 2021)
Tumor antigen positive cell lines were subsequently targeted by CAR NK cells (GTA102) to investigate the efficiency of antigen-specific targeting of resistant tumor cells. It is essential to evaluate the potency of cell-based immunotherapy products in both 2D and 3D settings to target solid tumors efficiently. Most importantly, our results demonstrate that introduction of CAR to NK cells significantly improves targeting of UCB-NK cell resistant antigen+ CRC cells and stands out as a potential cell therapy product for the treatment of colorectal cancer patients.
Preclinical • IO biomarker
|
CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
GTA102 • oNKord (inaleucel)